SOHO 2022 | Novel non-immunological agents currently under investigation for CLL
Alexey Danilov
• 28 Sep 2022
In this video, Alexey V. Danilov, MD, PhD, City of Hope, Duarte, CA, highlights novel agents under investigation for the treatment of chronic lymphocytic leukemia (CLL), drawing focus on non-covalent BTK inhibitors such as pirtobrutinib and nemtabrutinib. Prof. Danilov also highlights the promise of BTK degraders and other targeted agents, including BCL2 and BCLxL inhibitors. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
